DUBLIN–(BUSINESS WIRE)–The “Mergers and Acquisitions (M&A) in the Pharmaceutical Contract Manufacturing Industry – Implications and Outlook – 2021 Edition” report has been added to ResearchAndMarkets.com’s offering.
This report is the third edition of our analysis of mergers and acquisitions in the pharmaceutical contract manufacturing industry.
This report gives important, expert insight you won’t find in any other source. 28 tables and figures throughout the report illustrate major points and trends.
Scope
This report is required reading for:
- CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
- Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
- Private equity and Stock analysts: target identification and analysis, portfolio company performance benchmarking
Reasons to Buy
- Overview of M&A in the Pharma CMO Industry
- Detailed view of CDMO performance by number of deals completed from the publisher’s Deals database
- Analysis of the M&A of specific manufacturing services
Key Topics Covered:
Executive Summary
- Players
- Trends
Industry Analysis
- Objectives and Methodology
- Overview of M&A Activity 2018-2020
- Target Characteristics
- Acquirer Characteristics
- Geography
- Top Acquirers
Segment Close-Ups of M&A Activity, 2018-2020
- API-Biologic
- API-Small Molecule
- Commercial Dose Manufacturing
- Analytical Services
- Packaging
- Deal Advisors
- Top Financial Advisors
- Top Legal Advisors
Valuations
- Facility Acquisitions
- What It Means
- The Outlook for M&A
- API-Biologic Targets
- Past Predictions
- Value Chain
- Companies
Appendix
For more information about this report visit https://www.researchandmarkets.com/r/6ydj14
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900